EU approves AZ’ potassium binder for hyperkalaemia
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
Hyperkalaemia is characterised by elevated potassium levels in the blood. Risk of developing the condition increases significantly for patients with chronic kidney disease and for those who take common life-saving medications for heart failure, such as renin-angiotensin-aldosterone system (RAAS) inhibitors, which can increase potassium in the blood.
To help prevent the recurrence of hyperkalaemia, RAAS-inhibitor therapy is often modified or discontinued, but this can compromise cardio-renal outcomes and increase the risk of death, the firm noted.
Read more: http://www.pharmatimes.com/news/eu_approves_az_potassium_binder_for_hyperkalaemia_1229022
Hyperkalaemia is characterised by elevated potassium levels in the blood. Risk of developing the condition increases significantly for patients with chronic kidney disease and for those who take common life-saving medications for heart failure, such as renin-angiotensin-aldosterone system (RAAS) inhibitors, which can increase potassium in the blood.
To help prevent the recurrence of hyperkalaemia, RAAS-inhibitor therapy is often modified or discontinued, but this can compromise cardio-renal outcomes and increase the risk of death, the firm noted.
Read more: http://www.pharmatimes.com/news/eu_approves_az_potassium_binder_for_hyperkalaemia_1229022